Omega 3 fatty acids reduce myeloid progenitor cell frequency in the bone marrow of mice and promote progenitor cell differentiation

Omega 3 fatty acids reduce myeloid progenitor cell frequency in the bone marrow of mice and promote progenitor cell differentiation
复制标题

DOI:
10.1186/1476-511x-8-9
复制
发表时间:
2009-03-18
影响因子:
4.5
通讯作者:
Sollars, Vincent E.
Sollars, Vincent E.
中科院分区:
医学3区
文献类型:
--
作者:
Varney, Melinda E.;Hardman, W. Elaine;Sollars, Vincent E.

文献摘要

被引文献

相似文献

研究背景:Omega - 3脂肪酸在多种细胞类型中具有抑制增殖、诱导凋亡和促进分化的作用。细胞的存活、扩增和分化过程在造血过程中起着至关重要的作用。我们研究了omega - 3脂肪酸在控制小鼠骨髓中各种髓祖细胞频率中的作用。祖细胞频率增加和分化受阻是髓系造血疾病的特征,如骨髓增生性疾病和髓系白血病。结果:我们发现增加饮食中omega - 3脂肪酸的比例相对于omega - 6脂肪酸的比例会导致小鼠骨髓中骨髓祖细胞分化增加,频率降低。此外,这对外周血白细胞计数没有不利影响。结论:我们的研究结果表明,omega - 3脂肪酸通过降低骨髓中骨髓祖细胞的频率和促进祖细胞的分化来影响造血分化。对这一发现的进一步探索可能会导致使用omega - 3脂肪酸作为各种造血疾病患者的治疗选择。
Background: Omega 3 fatty acids have been found to inhibit proliferation, induce apoptosis, and promote differentiation in various cell types. The processes of cell survival, expansion, and differentiation are of key importance in the regulation of hematopoiesis. We investigated the role of omega 3 fatty acids in controlling the frequency of various myeloid progenitor cells in the bone marrow of mice. Increased progenitor cell frequency and blocked differentiation are characteristics of hematopoietic disorders of the myeloid lineage, such as myeloproliferative diseases and myeloid leukemias.Results: We found that increasing the proportion of omega 3 fatty acids relative to the proportion of omega 6 fatty acids in the diet caused increased differentiation and reduced the frequency of myeloid progenitor cells in the bone marrow of mice. Furthermore, this had no adverse effect on peripheral white blood cell counts.Conclusion: Our results indicate that omega 3 fatty acids impact hematopoietic differentiation by reducing myeloid progenitor cell frequency in the bone marrow and promoting progenitor cell differentiation. Further exploration of this discovery could lead to the use of omega 3 fatty acids as a therapeutic option for patients that have various disorders of hematopoiesis.